A Study of Pemetrexed Plus Cisplatin in Patients With Refractory Soft Tissue Sarcoma

Inclusion Criteria: 1. Histologically confirmed advanced bone and soft tissue sarcoma with prior chemotherapy including anthracycline or ifosfamide 2. Measurable or evaluable disease (RECIST 1.1.) 3. Age ≥19 years 4. ECOG performance status of 0-2 5. Adequate laboratory findings * Absolute neutrophil count (ANC) ≥ 1500 /µL * Platelet count ≥ 75,000/ µL * Serum creatinine \< 1.5 x upper limit of normal (ULN) * AST (SGOT) and ALT (SGPT) \< 3 x upper limit of normal (ULN) * Total bilirubin \<1.5 x upper limit of normal (ULN) 6. more than 3 months of expected survival 7. Provision of written informed consent prior to any study procedure Exclusion Criteria: 1. Patient who has had chemotherapy, radiotherapy, or biological therapy within 2 weeks prior to entering the study' 2. Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study. 3. Resectable lung metastases 4. Uncontrolled or active CNS metastasis and/or carcinomatous meningitis 5. Other co-existing malignancies or malignancies diagnosed within the last 3 years with the exception of basal cell carcinoma, thyroid cancer or cervical cancer in situ. 6. Uncontrolled medical conditions